Showing 641-650 of 1563 results for "".
Elacestrant and Targeted Therapies in Breast Cancer: Preliminary Data From ELECTRA and ELEVATE
https://reachmd.com/programs/project-oncology/elacestrant-and-targeted-therapies-in-breast-cancer-preliminary-data-from-electra-and-elevate/35865/A pooled analysis of the ELECTRA and ELEVATE trials, which evaluated elacestrant in combination with PI3K, AKT, mTOR, and CDK4/6 inhibitors in patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer, showed promising preliminary data. Hear from Drs. Jennifer Caudle andTimely LDL-C Management: Data From a Real-World Setting
https://reachmd.com/programs/medical-industry-feature/timely-ldl-c-management-data-from-a-real-world-setting/29763/Explore the efficacy and safety of prompt addition of a non-statin lipid lowering therapy for post-event LDL-C management.Breaking the Cycle: Understanding and Managing Inflammatory Memory in Psoriasis
https://reachmd.com/programs/clinicians-roundtable/breaking-the-cycle-understanding-and-managing-inflammatory-memory-in-psoriasis/32446/Inflammatory memory may influence symptom recurrence in psoriasis patients. Learn about how it works and strategies for promoting sustained remission.Exploring Elacestrant Combinations for ER+/HER2- mBC: Early Data from ELEVATE
https://reachmd.com/programs/project-oncology/exploring-elacestrant-combinations-for-erher2-mbc-early-data-from-elevate/35864/Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the ELEVATE study highlights promising early data on elacestrant in combination with targeted agents for patients with ER-positive, HER2-negative metastatic breast cancer (mBC). With a focus on overcoming endocrine reSpring Cleaning Your Practice: What Should You Keep, Toss, or Change?
https://modernaesthetics.com/topics/practice-development/spring-cleaning-your-practice-what-should-you-keep-toss-or-change/35156/Axatilimab for cGVHD: Assessing Organ-Specific Responses in AGAVE-201
https://reachmd.com/programs/project-oncology/axatilimab-for-cgvhd-assessing-organ-specific-responses-in-agave-201/36313/An analysis of the AGAVE-201 trial presented at the European Hematology Association 2025 Congress evaluated the organ-specific responses to axatilimab in patients with chronic graft-versus-host disease (cGVHD). Finding a range of effects, these results could offer new insights into dose optimizationA Clear Horizon in Plaque Psoriasis: Exploring the Role of Investigational Oral Therapies
https://reachmd.com/programs/cme/a-clear-horizon-in-plaque-psoriasis-exploring-the-role-of-investigational-oral-therapies/29800/Tune in to learn more about the role of investigational oral therapies in treating plaque psoriasis.Predicting Patients’ Immune Response to Viral Infections with AI
https://reachmd.com/programs/covid-19-frontlines/predicting-patients-immune-response-to-viral-infections-with-ai/12829/It can be difficult to determine how patients infected with COVID-19 will fare. But could artificial intelligence help us predict the answer?The Battle of Biostimulators: PLLA vs hyperdilute CaHA
https://modernaesthetics.com/ma-issues-index/july-august-2025/biostimulators-PLLA-vs-HyperdiluteCaHA/36663/Key takeaways from Dr. Kay Durairaj's YoungMD Connect workshopAddressing COPD Exacerbations With Urgency
https://reachmd.com/programs/medical-industry-feature/addressing-copd-exacerbations-with-urgency/24225/Hear about the burden of chronic obstructive pulmonary disease (COPD) exacerbations and the role of early diagnosis and proactive care in addressing them.